Literature DB >> 33915763

Persistence of Anti-Hbs after up to 30 Years in Health Care Workers Vaccinated against Hepatitis B Virus.

Silvia Cocchio1, Vincenzo Baldo1, Anna Volpin1, Marco Fonzo1, Annarosa Floreani2,3, Patrizia Furlan1, Paola Mason1, Andrea Trevisan1, Maria Luisa Scapellato1.   

Abstract

The burden of hepatitis B virus (HBV) infection is a serious public health problem all over the world. Vaccination remains the most effective prevention measure, and safe and effective HBV vaccines have been available since 1982. Health care workers (HCWs) vaccinated against HBV and prospectively followed up for at least 14 years were classified by their antibody titers after primary vaccination as: poor responders (10-99 mIU/mL); moderate responders (100-999 mIU/mL); and good responders (≥1000 mIU/mL). The incidence of antibody loss was calculated for 1000 person-years and the anti-HBs persistence was calculated. The analysis concerned 539 HCWs: 494 good responders (91.7%); 37 moderate responders (6.9%); and eight poor responders (1.5%). The incidence of anti-HBs loss was 52.1 per 1000 person-years for the poor responders, 11.3 per 1000 person-years for the moderate responders, and 1.4 per 1000 person-years for the good responders. The mean persistence of anti-HBs differed significantly between the three groups, being: 19.2 years (95% CI: 15.6-22.8), 25.4 years (95% CI: 23.0-27.9), and 31.0 years (95% CI: 30.5-31.5) for the poor, moderate and good responders, respectively. In conclusion, our findings demonstrate a good persistence of protective anti-HBs titers in HCWs exposed to occupational risk for up to 30 years after a primary vaccination cycle (even without a booster dose) if their titer was initially higher than 100 mIU/mL.

Entities:  

Keywords:  HBV; anti-HBs; health care workers; vaccination

Year:  2021        PMID: 33915763     DOI: 10.3390/vaccines9040323

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN: 2076-393X


  5 in total

1.  Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer's BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study.

Authors:  Momoko Iwamoto; Akira Ukimura; Taku Ogawa; Fumiko Kawanishi; Naofumi Osaka; Mari Kubota; Tatsuhiko Mori; Ritsuko Sawamura; Masami Nishihara; Tomio Suzuki; Kazuhisa Uchiyama
Journal:  PLoS One       Date:  2022-05-16       Impact factor: 3.752

2.  Screening of Hepatitis A and B Seropositivity among Turkish Healthcare Providers Admitted to Occupational Health Services.

Authors:  Melike Mercan Başpınar
Journal:  Int J Clin Pract       Date:  2022-02-21       Impact factor: 3.149

Review 3.  Undetectable Anti-HBs Antibodies: Need of a Booster Dose for HIV-1-Infected Individuals.

Authors:  Yonas Bekele; Jay A Berzofsky; Francesca Chiodi
Journal:  Vaccines (Basel)       Date:  2021-12-15

4.  12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial.

Authors:  Bingfeng Han; Wu Liu; Juan Du; Hanyu Liu; Tianshuo Zhao; Shubo Yang; Shuai Wang; Sihui Zhang; Bei Liu; Yaqiong Liu; Fuqiang Cui
Journal:  Vaccines (Basel)       Date:  2021-11-29

5.  Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.

Authors:  Moses Ocan; Frances Acheng; Carol Otike; Judith Beinomugisha; David Katete; Celestino Obua
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.